Literature DB >> 6288258

Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus.

J Papkoff, I M Verma, T Hunter.   

Abstract

We identified, in cells transformed by Moloney murine sarcoma virus (M-MuSV clone 124), a protein encoded by the M-MuSV transforming gene, v-mos. An antiserum against a synthetic peptide corresponding to the C terminus of a protein predicted from the v-mos nucleotide sequence specifically recognizes a protein doublet of approximately 37,000 daltons from 35S-methionine-labeled M-MuSV 124-transformed producer cells. By peptide mapping, this protein is almost identical to the 37 kd in vitro translation product from the M-MuSV v-mos gene. Immunoprecipitates from 32P-labeled cells contain a single v-mos-specific phosphoprotein, which has at least six sites of phosphorylation containing phosphoserine. Pulse-chase experiments show that the lower band in the 35S-methionine-labeled doublet is the primary translation product, which is modified, probably by phosphorylation, to yield the upper band. A similar mos protein is immunoprecipitated from HT1-MuSV-transformed cells, but not from uninfected NIH/3T3 cells. These mos proteins are present at very low levels in transformed cell lines. Cells acutely infected with M-MuSV 124, however, transiently contain much higher levels of the mos protein. These high levels coincide with extensive cell mortality.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6288258     DOI: 10.1016/0092-8674(82)90158-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  56 in total

1.  mos gene transforming efficiencies correlate with oocyte maturation and cytostatic factor activities.

Authors:  N Yew; M Oskarsson; I Daar; D G Blair; G F Vande Woude
Journal:  Mol Cell Biol       Date:  1991-02       Impact factor: 4.272

2.  v-mos protein produced by in vitro translation has protein kinase activity.

Authors:  N K Herzog; M Nash; L S Ramagli; R B Arlinghaus
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

3.  Perturbed hemopoiesis and the generation of multipotential stem cell clones in src-infected bone marrow cultures is an indirect or transient effect of the oncogene.

Authors:  J A Wyke; A W Stoker; S Searle; E Spooncer; P Simmons; T M Dexter
Journal:  Mol Cell Biol       Date:  1986-03       Impact factor: 4.272

4.  Nucleoside triphosphate-dependent DNA-binding properties of mos protein.

Authors:  A Seth; E Priel; G F Vande Woude
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

5.  The P55 protein affected by v-mos expression is vimentin.

Authors:  B Singh; R Goldman; L Hutton; N K Herzog; R B Arlinghaus
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

6.  Long terminal repeat sequences impart hematopoietic transformation properties to the myeloproliferative sarcoma virus.

Authors:  C Stocking; R Kollek; U Bergholz; W Ostertag
Journal:  Proc Natl Acad Sci U S A       Date:  1985-09       Impact factor: 11.205

7.  Use of site-specific antipeptide antibodies to perturb the serine kinase catalytic activity of p37mos.

Authors:  S A Maxwell; R B Arlinghaus
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

8.  p37mos-associated serine/threonine protein kinase activity correlates with the cellular transformation function of v-mos.

Authors:  B Singh; M Hannink; D J Donoghue; R B Arlinghaus
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

9.  Antibodies of predetermined specificity detect two retroviral oncogene products and inhibit their kinase activities.

Authors:  S Sen; R A Houghten; C J Sherr; A Sen
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

10.  Comparison of myeloproliferative sarcoma virus with Moloney murine sarcoma virus variants by nucleotide sequencing and heteroduplex analysis.

Authors:  A Stacey; C Arbuthnott; R Kollek; L Coggins; W Ostertag
Journal:  J Virol       Date:  1984-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.